Female Testosterone Levels: Normal Ranges and Clinical Approach
Normal adult female testosterone levels range from approximately 15-46 ng/dL (520-1595 pmol/L) for total testosterone and 1.2-6.4 pg/mL (4.16-22.2 pmol/L) for free testosterone in a typical 30-year-old woman, with levels declining progressively with age. 1
Normal Reference Ranges
Age-Specific Considerations
Female testosterone levels are not static across the lifespan and require age-adjusted interpretation:
Premenopausal women (18-49 years): Total testosterone exhibits a steep age-related decline, particularly pronounced in the early reproductive years rather than at menopause 2
For a 30-year-old woman 1:
- Total testosterone: 15-46 ng/dL (520-1595 pmol/L)
- Free testosterone: 1.2-6.4 pg/mL (4.16-22.2 pmol/L)
- Bioavailable testosterone: 1.12-7.62 ng/dL (38.8-264.21 pmol/L)
- SHBG: 18-86 nmol/L
Age 19-59 years: Recent large-scale analysis demonstrates testosterone follows a weakly skew-normal distribution where the mean decreases and variance increases linearly with age 3
Postmenopausal women: Testosterone levels decline by approximately 50% from the early 20s to mid-40s, with continued decline thereafter 4
Menstrual Cycle Variations
Testosterone shows a small mid-cycle increase, but this variation is minor compared to overall variability, so reference ranges can be applied regardless of cycle timing 1
Critical Diagnostic Limitations
The Measurement Problem
Current commercially available testosterone assays are inadequate for accurately measuring female testosterone levels 5, 6. The Endocrine Society explicitly states:
- Standard immunoassays lack sufficient sensitivity and specificity for the low concentrations found in women 6
- Different proprietary assays produce significantly different results for the same sample 6
- At female testosterone concentrations, values have "little utility" 6
The Diagnostic Dilemma
The Endocrine Society recommends AGAINST making a clinical diagnosis of androgen deficiency syndrome in women because 5:
- No well-defined clinical syndrome exists
- Data correlating androgen levels with specific signs or symptoms are unavailable
- There is neither a well-defined clinical syndrome nor normative data that can define the disorder 6
Evaluation Approach
When to Measure Testosterone
Do NOT routinely measure testosterone in women for diagnosis, as correlation between symptoms and testosterone levels has not been established 5. However, if measurement is pursued:
- Use morning blood samples (testosterone exhibits diurnal variation)
- Measure during follicular phase if timing is practical, though not mandatory 1
- Require sensitive assays validated for female ranges (liquid chromatography-tandem mass spectrometry preferred over immunoassays) 6
- Measure sex hormone-binding globulin (SHBG) to calculate free testosterone 1
Conditions Associated with Low Testosterone
Women with the following conditions have documented low androgen levels but routine treatment is NOT recommended 5:
- Hypopituitarism
- Adrenal insufficiency
- Bilateral oophorectomy (particularly in women ≥55 years, who show significantly lower total and free testosterone) 2
- Glucocorticoid therapy
- Oral contraceptive use
- Oral estrogen therapy
Treatment Recommendations
General Stance on Testosterone Therapy
The Endocrine Society recommends AGAINST generalized use of testosterone in women for 5:
- Infertility
- Sexual dysfunction (except hypoactive sexual desire disorder - see below)
- Cognitive dysfunction
- Cardiovascular dysfunction
- Metabolic dysfunction
- Bone health
- General well-being
Rationale: Indications are inadequate, evidence of long-term safety is lacking, and government-approved dose-appropriate preparations are not widely available 5
The ONE Exception: Hypoactive Sexual Desire Disorder (HSDD)
Postmenopausal women with decreased sexual desire causing personal distress may be candidates for testosterone therapy IF 7:
- No other identifiable cause exists (rule out physical factors, psychosocial factors, medications)
- Physiologic cause for reduced testosterone exists (e.g., bilateral oophorectomy)
- Patient is estrogen-replete
- Evidence from randomized trials shows testosterone improves sexual desire, arousal, and orgasmic response in postmenopausal women 7
Contraindications to Testosterone Therapy
Absolute contraindications 7:
- Breast cancer
- Uterine cancer
- Cardiovascular disease
- Liver disease
Relative contraindications 8:
- Sleep apnea
- Peripheral edema
- Erythrocytosis (hematocrit >52%)
- Benign prostatic hyperplasia (not applicable to women, but polycythemia concerns remain)
If Testosterone Therapy Is Prescribed
Formulation preferences 7:
- Use transdermal patches or topical gels/creams (NOT oral formulations due to first-pass hepatic effects)
- Avoid testosterone preparations formulated for men due to excessive dosing risk 5
- Use caution with custom-compounded products due to inconsistent dosing 7
Monitoring protocol 5:
- Check baseline testosterone level before treatment
- Monitor testosterone levels at 3-6 weeks after initiation to assess for overuse
- Review levels every 6 months to monitor for excessive use and signs of androgen excess
- Assess for hirsutism and acne (documented adverse effects) 7
- Monitor subjective sexual response, desire, and satisfaction 7
- Goal: Maintain levels in physiologic female range (NOT supraphysiologic)
Treatment principles 7:
- Administer at lowest dose for shortest time that meets treatment goals
- Provide counseling on potential risks and benefits before initiating
- Testosterone treatment without concomitant estrogen therapy cannot be recommended in postmenopausal women due to lack of evidence 7
DHEA Therapy
The Endocrine Society recommends AGAINST generalized use of DHEA in women because indications are inadequate and evidence of efficacy and long-term safety are lacking 5. This includes women with adrenal insufficiency, where routine DHEA use is not recommended due to limited effectiveness and safety data 5.
Key Clinical Pitfalls
Do not diagnose "androgen deficiency" based on laboratory values alone - no validated syndrome exists 5
Do not use standard male testosterone assays - they are insufficiently sensitive for female ranges 6
Do not assume menopause causes testosterone decline - the decline is age-related and begins in the 20s-30s, not at menopause 2
Do not prescribe testosterone for non-specific symptoms like fatigue or decreased well-being without meeting specific HSDD criteria 5
Do not use oral testosterone preparations in women due to hepatic effects 7
Do not continue therapy beyond 6 months without evidence of benefit - long-term safety data are lacking 7